Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a mo… Read more
Kiniksa Pharmaceuticals Ltd (KNSA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.063x
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has a cash flow conversion efficiency ratio of 0.063x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($33.68 Million) by net assets ($535.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kiniksa Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kiniksa Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
0.063x |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
-0.076x |
|
Investment AB Latour (publ)
OTCGREY:IVTBF
|
0.037x |
|
City Holding Company
NASDAQ:CHCO
|
0.042x |
|
Jiangxi Jovo Energy Co. Ltd
SHG:605090
|
-0.003x |
|
Inter & Co. Inc. Class A Common Shares
NASDAQ:INTR
|
0.126x |
|
SJW Group Common Stock
NYSE:SJW
|
0.031x |
|
Organon & Co
NYSE:OGN
|
0.291x |
Annual Cash Flow Conversion Efficiency for Kiniksa Pharmaceuticals Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Kiniksa Pharmaceuticals Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $438.44 Million | $25.69 Million | 0.059x | +93.31% |
| 2023-12-31 | $438.84 Million | $13.30 Million | 0.030x | +106.77% |
| 2022-12-31 | $396.15 Million | $5.81 Million | 0.015x | +102.15% |
| 2021-12-31 | $185.04 Million | $-126.30 Million | -0.683x | -55.94% |
| 2020-12-31 | $311.94 Million | $-136.53 Million | -0.438x | +37.70% |
| 2019-12-31 | $225.42 Million | $-158.37 Million | -0.703x | -142.18% |
| 2018-12-31 | $279.27 Million | $-81.01 Million | -0.290x | -151.82% |
| 2017-12-31 | $-89.71 Million | $-50.22 Million | 0.560x | -34.12% |
| 2016-12-31 | $-25.73 Million | $-21.87 Million | 0.850x | -- |